Cancer-associated thrombotic microangiopathy

Area of Science:

• Oncology
• Hematology
• Pathology

Background:

• Cancer-associated thrombotic microangiopathy (CATM) is a serious complication characterized by microvascular thrombosis, thrombocytopenia, and end-organ damage.
• Major subtypes include hemolytic uremic syndrome and thrombotic thrombocytopenic purpura.
• CATM can arise from the malignancy itself or as a consequence of cancer therapy.

Purpose of the Study:

• To review the etiology, pathogenesis, clinical manifestations, complications, and management of CATM.
• To highlight novel causative factors associated with new cancer therapies.
• To emphasize the importance of timely diagnosis and treatment.

Main Methods:

• Literature review of cancer-associated thrombotic microangiopathy.
• Analysis of etiological factors, pathogenic mechanisms, and clinical presentations.
• Evaluation of diagnostic approaches and therapeutic strategies.

Main Results:

• CATM encompasses disorders with microvascular thrombosis, thrombocytopenia, and ischemic organ damage.
• Emerging cancer treatments are identified as novel contributors to CATM.
• Effective management relies on correlating clinical findings and laboratory data.

Conclusions:

• CATM is a complex condition with diverse causes, including new cancer therapies.
• Early diagnosis through careful clinical and laboratory assessment is crucial.
• Prompt and appropriate treatment is essential for managing CATM in cancer patients.